rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2015-11-2-202-208rpcardio-153Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИTHE EFFECTIVENESS OF LERCANIDIPINE IN REDUCING THE RISK OF ARTERIAL HYPERTENSION COMPLICATIONSЭФФЕКТИВНОСТЬ ЛЕРКАНИДИПИНА В СНИЖЕНИИ РИСКА РАЗВИТИЯ ОСЛОЖНЕНИЙ ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИТрисветоваЕ. Л.TrisvetovaE. EL.

д.м.н., профессор, профессор 2-й кафедры внутренних болезней

220116, Минск, проспект Дзержинского, 83

Prospect Dzerzhinskogo 83, Minsk, 83220116 Belorussia

trisvet-47@mail.ruБелорусский государственный медицинский университетБеларусьBelarusian State Medical UniversityBelarus201523092015112202208Copyright © Trisvetova E.E., 20152015Трисветова Е.Л.Trisvetova E.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/153

Despite progress in reducing the risk of hypertension (HT) complications, control of blood pressure (BP) levels remains inadequate. Dihydropyridine calcium channel blockers show antihypertensive effect due to significant vasoselective action with a minimal impact on a conductive system of the heart. Lercanidipine is a dihydropyridine calcium channel blocker of the third generation with high lipophilicity and long-lasting action. Lercanidipine had shown both in monotherapy and in combination with ACE inhibitors or angiotensin II blockers the good antihypertensive effect with stable BP profile throughout the day, organoprotection that slowed down the progression of HT complications, metabolic neutrality and safety in mild to moderate HT.

Несмотря на прогресс в снижении риска развития осложнений артериальной гипертензии (АГ), контроль за уровнем артериального давления (АД) остается недостаточным. Дигидропиридиновые блокаторы кальциевых каналов проявляют антигипертензивный эффект за счет выраженного вазоселективного действия, оказывая ми-нимальное влияние на проводящую систему сердца. Лерканидипин – дигидропиридиновый блокатор кальциевых каналов третьего поколения с высокой липофиль-ностью и длительным действием, при монотерапии и в комбинации с ингибиторами АПФ или блокаторами ангиотензина II показал хороший антигипертензивный эффект со стабильным профилем АД в течение суток, органопротективное влияние, замедляющее прогрессирование осложнений, метаболическую нейтральность и без-опасность при мягкой и умеренной АГ.

артериальная гипертензияосложненияблокаторы кальциевых каналовлерканидипинarterial hypertensioncomplicationscalcium channel blockerslercanidipineReferences2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31(7):1281-357.2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31(7):1281-357.Costanzo S., Di Castelnuovo A., Zito F., et al. Prevalence, awareness, treatment and control of hypertension in healthy unrelated male-female pairs of European regions: the dietary habit profile in European communities with different risk of myocardial infarction - the impact of migration as a model of gene-environment interaction project. J Hypertens 2008;26(12):2303-11.Costanzo S., Di Castelnuovo A., Zito F., et al. Prevalence, awareness, treatment and control of hypertension in healthy unrelated male-female pairs of European regions: the dietary habit profile in European communities with different risk of myocardial infarction - the impact of migration as a model of gene-environment interaction project. J Hypertens 2008;26(12):2303-11.Boytsov SA, Balanova YA, Shalnova SA, et al. Hypertension among persons aged 25-64: prevalence, awareness, treatment and control. According to the materials is-following essay. Kardiovaskulyarnaya Terapiya i Profilaktika 2014; 4: 4-14. Russian (Бойцов С.А., Баланова Ю.А., Шальнова С.А., и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лече-ние и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная Терапия и Профилак-тика 2014;4:4-14).Boytsov SA, Balanova YA, Shalnova SA, et al. Hypertension among persons aged 25-64: prevalence, awareness, treatment and control. According to the materials is-following essay. Kardiovaskulyarnaya Terapiya i Profilaktika 2014; 4: 4-14. Russian (Бойцов С.А., Баланова Ю.А., Шальнова С.А., и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лече-ние и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная Терапия и Профилак-тика 2014;4:4-14).Shalnova SA. Epidemiology of hypertension in Russia: a portrait of the patient. Arterial'naya Gipertenziya 2008; 2 (2): 8-14. Russian (Шальнова С.А. Эпидемиология артериальной гипертензии в Рос-сии: портрет больного. Артериальная Гипертензия 2008;2(2):8-14).Shalnova SA. Epidemiology of hypertension in Russia: a portrait of the patient. Arterial'naya Gipertenziya 2008; 2 (2): 8-14. Russian (Шальнова С.А. Эпидемиология артериальной гипертензии в Рос-сии: портрет больного. Артериальная Гипертензия 2008;2(2):8-14).Mancia G., De Backer G., Dominiczak A., et al. Guidelines for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.Mancia G., De Backer G., Dominiczak A., et al. Guidelines for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.WHO - OSH Hypertension Guidelines Committee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.WHO - OSH Hypertension Guidelines Committee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.Bhatt D.L., Steg P.G., Ohman E.M. et al. International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295 (2):180-9.Bhatt D.L., Steg P.G., Ohman E.M. et al. International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295 (2):180-9.Timofeeva TN, Deev AD, Shalnova SA, et al. Analytical Review of the epidemic-logical situation AH in 2008 and its dynamics from 2003 to 2008 in three monitoring. Moscow: Ministry of Health of the Russian Federation, GSRC PM; 2009. Russian (Тимофеева Т.Н., Деев А.Д., Шальнова С.А., и др. Ана-литическая справка об эпидемиологической ситуации по АГ в 2008 году и ее динамике с 2003 по 2008 год по трем проведенным мониторингам. Москва: МЗ СР РФ, ГНИЦ ПМ; 2009).Timofeeva TN, Deev AD, Shalnova SA, et al. Analytical Review of the epidemic-logical situation AH in 2008 and its dynamics from 2003 to 2008 in three monitoring. Moscow: Ministry of Health of the Russian Federation, GSRC PM; 2009. Russian (Тимофеева Т.Н., Деев А.Д., Шальнова С.А., и др. Ана-литическая справка об эпидемиологической ситуации по АГ в 2008 году и ее динамике с 2003 по 2008 год по трем проведенным мониторингам. Москва: МЗ СР РФ, ГНИЦ ПМ; 2009).Chazova IE, Oshchepkova EV, Zhernakova YuV. Diagnosis and treatment of hypertension. Clinical guidelines. M .: RMOAG; 2013. Russian (Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Диагностика и лече-ние артериальной гипертонии. Клинические рекомендации. М.: РМОАГ; 2013).Chazova IE, Oshchepkova EV, Zhernakova YuV. Diagnosis and treatment of hypertension. Clinical guidelines. M .: RMOAG; 2013. Russian (Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Диагностика и лече-ние артериальной гипертонии. Клинические рекомендации. М.: РМОАГ; 2013).Kukes VG, editor. Clinical pharmacology. 4th edition. Moscow: GEOTAR Media; 2008. Russian (Ку-кес В.Г., редактор. Клиническая фармакология. Издание 4-е. М.:ГЭОТАР-Медиа; 2008).Kukes VG, editor. Clinical pharmacology. 4th edition. Moscow: GEOTAR Media; 2008. Russian (Ку-кес В.Г., редактор. Клиническая фармакология. Издание 4-е. М.:ГЭОТАР-Медиа; 2008).Belousov YB, Gurevich KG. General and private clinical pharmacokinetics. Moscow: Litterra; 2006. Russian (Белоусов Ю.Б., Гуревич К.Г. Общая и частная клиническая фармакокинетика. М.: Лит-терра; 2006).Belousov YB, Gurevich KG. General and private clinical pharmacokinetics. Moscow: Litterra; 2006. Russian (Белоусов Ю.Б., Гуревич К.Г. Общая и частная клиническая фармакокинетика. М.: Лит-терра; 2006).Bang L., Chapman T., Goa K. Lercanidipine - a review of its efficacy in management of hypertension. Drugs 2003;22:2449-272.Bang L., Chapman T., Goa K. Lercanidipine - a review of its efficacy in management of hypertension. Drugs 2003;22:2449-272.Angelico P., Guarneri L., Leonardi A., et al. Vascular-selective Effect of Lercanidipine and other 1,4-Dihydropyridines in Isolated Rabbit Tissues. J Pharmacy and Pharmacology 1999;6(51):709-14.Angelico P., Guarneri L., Leonardi A., et al. Vascular-selective Effect of Lercanidipine and other 1,4-Dihydropyridines in Isolated Rabbit Tissues. J Pharmacy and Pharmacology 1999;6(51):709-14.Cargononi A., Beningo M., Ferrari F. et al. Effects of lercanidipine and its enantiomers on ischemia and reperfusion. J Cardiovasc Pharmacol 1997:29 (suppl 1):S48- S62.Cargononi A., Beningo M., Ferrari F. et al. Effects of lercanidipine and its enantiomers on ischemia and reperfusion. J Cardiovasc Pharmacol 1997:29 (suppl 1):S48- S62.McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000;60:1123-40.McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000;60:1123-40.Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag 2005;1(3):173-82.Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag 2005;1(3):173-82.Burnier M., Gasser U.E. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert. Opin Pharmacother 2007;(8914):2215-23.Burnier M., Gasser U.E. Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert. Opin Pharmacother 2007;(8914):2215-23.Wu Y., Xu M., Wang H. et al. Lercanidipine hydrochloride versus felodipine sustained-release for mildto-moderate hypertension: a multi-center, randomized clinical trial. Current Medical Research & Opinion 2015;1(31):171-6.Wu Y., Xu M., Wang H. et al. Lercanidipine hydrochloride versus felodipine sustained-release for mildto-moderate hypertension: a multi-center, randomized clinical trial. Current Medical Research & Opinion 2015;1(31):171-6.Ghamami N., Chiang S.N., Dormuth C.Time course for blood pressure lowering of dihydropyridine calcium channel blockers. Cochrane Database Syst Rev 2014; CD010052.Ghamami N., Chiang S.N., Dormuth C.Time course for blood pressure lowering of dihydropyridine calcium channel blockers. Cochrane Database Syst Rev 2014; CD010052.Cicero A.F., Gerocarni B., Rosticci M. et al. Blood Pressure and Metabolic Effect of a Combination of Lercanidipine with Different Antihypertensive Drugs in Clinical Practice. Clin Exp Hypertens 2012;34 (2):113-7.Cicero A.F., Gerocarni B., Rosticci M. et al. Blood Pressure and Metabolic Effect of a Combination of Lercanidipine with Different Antihypertensive Drugs in Clinical Practice. Clin Exp Hypertens 2012;34 (2):113-7.Mancia G., Coca A., Chazova I., et al. Effects on office and home blood pressure of the lercanidipineenalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. J Hypertens 2014;32(8):1700-7.Mancia G., Coca A., Chazova I., et al. Effects on office and home blood pressure of the lercanidipineenalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. J Hypertens 2014;32(8):1700-7.De Ciuceis C.I.,Salvetti M., Rossini C., et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens 2014;32 (3):565-574.De Ciuceis C.I.,Salvetti M., Rossini C., et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens 2014;32 (3):565-574.Cao T.S., Huynh V.M., Tran V.H. Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. Med Res Opin 2015;31(1):163-70.Cao T.S., Huynh V.M., Tran V.H. Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. Med Res Opin 2015;31(1):163-70.Sakurai-Yamashita Y., Harada N., Niwa M. Lercanidipine Rescues Hippocampus Pyramidal Neurons from Mild Ischemia-Induced Delayed Neuronal Death in SHRSP. Cell Mol Neurobiol 2011;31(4):561-7.Sakurai-Yamashita Y., Harada N., Niwa M. Lercanidipine Rescues Hippocampus Pyramidal Neurons from Mild Ischemia-Induced Delayed Neuronal Death in SHRSP. Cell Mol Neurobiol 2011;31(4):561-7.Peng MI, Jiang XJ, Dong H, et al. lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention? Curr Med Res Opin 2015;31(1):177-82.Peng MI, Jiang XJ, Dong H, et al. lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention? Curr Med Res Opin 2015;31(1):177-82.Robles N.R., Ocon J., Gomez C.F. et al. Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA Study. Renal Failure 2005;1:73-80.Robles N.R., Ocon J., Gomez C.F. et al. Lercanidipine in Patients with Chronic Renal Failure: The ZAFRA Study. Renal Failure 2005;1:73-80.

The authors declare that there are no conflicts of interest present.